Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study
Abstract Background BRAF V600E-mutant colorectal cancers (CRCs) are associated with shorter survival than BRAF wild-type tumors. Therapeutic decision-making for colorectal liver metastases (CRLM) harboring this mutation remains difficult due to the scarce literature. The aim was to study a large coh...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-04-01
|
| Series: | World Journal of Surgical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12957-022-02594-2 |
| _version_ | 1817990897940299776 |
|---|---|
| author | Sahir Javed Stéphane Benoist Patrick Devos Stéphanie Truant Rosine Guimbaud Astrid Lièvre David Sefrioui Romain Cohen Pascal Artru Aurélien Dupré Jean-Baptiste Bachet Christelle de la Fouchardière Anne Ploquin Anthony Turpin |
| author_facet | Sahir Javed Stéphane Benoist Patrick Devos Stéphanie Truant Rosine Guimbaud Astrid Lièvre David Sefrioui Romain Cohen Pascal Artru Aurélien Dupré Jean-Baptiste Bachet Christelle de la Fouchardière Anne Ploquin Anthony Turpin |
| author_sort | Sahir Javed |
| collection | DOAJ |
| description | Abstract Background BRAF V600E-mutant colorectal cancers (CRCs) are associated with shorter survival than BRAF wild-type tumors. Therapeutic decision-making for colorectal liver metastases (CRLM) harboring this mutation remains difficult due to the scarce literature. The aim was to study a large cohort of BRAF V600E-mutant CRLM patients in order to see if surgery extend overall survival among others prognostic factors. Methods BRAF V600E-mutant CRCs diagnosed with liver-only metastases, resected or not, were retrospectively identified between April 2008 and December 2017, in 25 French centers. Clinical, molecular, pathological characteristics and treatment features were collected. Overall survival (OS) was defined as the time from CRLM diagnosis to death from any cause. Cox proportional hazard models were used for statistical analysis. Results Among the 105 patients included, 79 (75%) received chemotherapy, 18 (17%) underwent upfront CRLM surgery, and 8 (8%) received exclusive best supportive care. CRLM surgery was performed in 49 (46.7%) patients. CRLM were mainly synchronous (90%) with bilobar presentation (61%). The median OS was 34 months (range, 28.9–67.3 months) for resected patients and 10.6 (6.7–12.5) months for unresected patients (P < 0.0001). In multivariate analysis, primary tumor surgery (hazard ratio (HR) = 0.349; 95% confidence interval (CI) 0.164–0.744, P = 0.0064) and CRLM resection (HR = 0.169; 95% CI 0.082–0.348, P < 0.0001) were associated with significantly better OS. Conclusions In the era of systemic cytotoxic chemotherapies, liver surgery seems to extend OS in BRAF V600E-mutant CRCs with liver only metastases historical cohort. |
| first_indexed | 2024-04-14T01:05:15Z |
| format | Article |
| id | doaj.art-396f97762c6d4546b3a537ee0d4435cb |
| institution | Directory Open Access Journal |
| issn | 1477-7819 |
| language | English |
| last_indexed | 2024-04-14T01:05:15Z |
| publishDate | 2022-04-01 |
| publisher | BMC |
| record_format | Article |
| series | World Journal of Surgical Oncology |
| spelling | doaj.art-396f97762c6d4546b3a537ee0d4435cb2022-12-22T02:21:15ZengBMCWorld Journal of Surgical Oncology1477-78192022-04-0120111010.1186/s12957-022-02594-2Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric studySahir Javed0Stéphane Benoist1Patrick Devos2Stéphanie Truant3Rosine Guimbaud4Astrid Lièvre5David Sefrioui6Romain Cohen7Pascal Artru8Aurélien Dupré9Jean-Baptiste Bachet10Christelle de la Fouchardière11Anne Ploquin12Anthony Turpin13Department of Medical Oncology, Centre Oscar LambretDepartment of Digestive Surgery and Surgical Oncology, Bicêtre Hospital, AP-HP, Paris–Sud UniversityUniversity of Lille, CHU LilleDepartment of Digestive Surgery and Transplantation, CHU LilleDepartment of Medical Oncology, Claudius Regaud InstituteDepartment of Gastroenterology, CHU Pontchaillou, Rennes 1 UniversityDigestive Oncology Unit, Department of Hepatogastroenterology, Rouen University Hospital, Normandie Université, UNIROUENMedical Oncology Department, Saint-Antoine Hospital, Sorbonne UniversityDepartment of Gastroenterology, Jean Mermoz HospitalDepartment of Surgical Oncology, Leon Berard Cancer Center, UNICANCERDepartment of Hepato-Gastroenterology, Hôpital Pitié Salpêtrière, Assistance Publique – Hôpitaux de Paris (AP-HP)Medical Oncology Department, Centre Leon Berard, Lyon I UniversityDepartment of Oncology, CHU LilleUniv. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to TherapiesAbstract Background BRAF V600E-mutant colorectal cancers (CRCs) are associated with shorter survival than BRAF wild-type tumors. Therapeutic decision-making for colorectal liver metastases (CRLM) harboring this mutation remains difficult due to the scarce literature. The aim was to study a large cohort of BRAF V600E-mutant CRLM patients in order to see if surgery extend overall survival among others prognostic factors. Methods BRAF V600E-mutant CRCs diagnosed with liver-only metastases, resected or not, were retrospectively identified between April 2008 and December 2017, in 25 French centers. Clinical, molecular, pathological characteristics and treatment features were collected. Overall survival (OS) was defined as the time from CRLM diagnosis to death from any cause. Cox proportional hazard models were used for statistical analysis. Results Among the 105 patients included, 79 (75%) received chemotherapy, 18 (17%) underwent upfront CRLM surgery, and 8 (8%) received exclusive best supportive care. CRLM surgery was performed in 49 (46.7%) patients. CRLM were mainly synchronous (90%) with bilobar presentation (61%). The median OS was 34 months (range, 28.9–67.3 months) for resected patients and 10.6 (6.7–12.5) months for unresected patients (P < 0.0001). In multivariate analysis, primary tumor surgery (hazard ratio (HR) = 0.349; 95% confidence interval (CI) 0.164–0.744, P = 0.0064) and CRLM resection (HR = 0.169; 95% CI 0.082–0.348, P < 0.0001) were associated with significantly better OS. Conclusions In the era of systemic cytotoxic chemotherapies, liver surgery seems to extend OS in BRAF V600E-mutant CRCs with liver only metastases historical cohort.https://doi.org/10.1186/s12957-022-02594-2Colorectal cancerBRAF mutationDrug therapyLiver metastasis surgery |
| spellingShingle | Sahir Javed Stéphane Benoist Patrick Devos Stéphanie Truant Rosine Guimbaud Astrid Lièvre David Sefrioui Romain Cohen Pascal Artru Aurélien Dupré Jean-Baptiste Bachet Christelle de la Fouchardière Anne Ploquin Anthony Turpin Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study World Journal of Surgical Oncology Colorectal cancer BRAF mutation Drug therapy Liver metastasis surgery |
| title | Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study |
| title_full | Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study |
| title_fullStr | Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study |
| title_full_unstemmed | Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study |
| title_short | Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study |
| title_sort | prognostic factors of braf v600e colorectal cancer with liver metastases a retrospective multicentric study |
| topic | Colorectal cancer BRAF mutation Drug therapy Liver metastasis surgery |
| url | https://doi.org/10.1186/s12957-022-02594-2 |
| work_keys_str_mv | AT sahirjaved prognosticfactorsofbrafv600ecolorectalcancerwithlivermetastasesaretrospectivemulticentricstudy AT stephanebenoist prognosticfactorsofbrafv600ecolorectalcancerwithlivermetastasesaretrospectivemulticentricstudy AT patrickdevos prognosticfactorsofbrafv600ecolorectalcancerwithlivermetastasesaretrospectivemulticentricstudy AT stephanietruant prognosticfactorsofbrafv600ecolorectalcancerwithlivermetastasesaretrospectivemulticentricstudy AT rosineguimbaud prognosticfactorsofbrafv600ecolorectalcancerwithlivermetastasesaretrospectivemulticentricstudy AT astridlievre prognosticfactorsofbrafv600ecolorectalcancerwithlivermetastasesaretrospectivemulticentricstudy AT davidsefrioui prognosticfactorsofbrafv600ecolorectalcancerwithlivermetastasesaretrospectivemulticentricstudy AT romaincohen prognosticfactorsofbrafv600ecolorectalcancerwithlivermetastasesaretrospectivemulticentricstudy AT pascalartru prognosticfactorsofbrafv600ecolorectalcancerwithlivermetastasesaretrospectivemulticentricstudy AT aureliendupre prognosticfactorsofbrafv600ecolorectalcancerwithlivermetastasesaretrospectivemulticentricstudy AT jeanbaptistebachet prognosticfactorsofbrafv600ecolorectalcancerwithlivermetastasesaretrospectivemulticentricstudy AT christelledelafouchardiere prognosticfactorsofbrafv600ecolorectalcancerwithlivermetastasesaretrospectivemulticentricstudy AT anneploquin prognosticfactorsofbrafv600ecolorectalcancerwithlivermetastasesaretrospectivemulticentricstudy AT anthonyturpin prognosticfactorsofbrafv600ecolorectalcancerwithlivermetastasesaretrospectivemulticentricstudy |